p53 and bcl-2 expression do not correlate with prognosis in primary cutaneous large T-cell lymphomas

Journal of Cutaneous Pathology

Volumn 24, Issue 8, 1997, Pages 462-467

  Van Haselen, Christian W ^a   Vermeer, Maarten H ^b   Toonstra, Johan ^a   Van Der Putte, Sebastian C J ^a   Mulder, P G H ^c   Van Vloten, Willem A ^a   Willemze, Rein ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD30 ANTIGEN; PROTEIN BCL 2; PROTEIN P53;

ADULT; ARTICLE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MYCOSIS FUNGOIDES; PROGNOSIS; PROTO ONCOGENE; SEZARY SYNDROME; SKIN LYMPHOMA; T CELL LYMPHOMA; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD30; ANTIGENS, NUCLEAR; BIOLOGICAL MARKERS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LYMPHOMA, T-CELL, CUTANEOUS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; SKIN NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030860272     PISSN: 03036987     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0560.1997.tb01319.x     Document Type: Article

References (28)

1. Willemze R, Beljaards RC, Meijer CJLM. Classification of primary cutaneous T-cell lymphoma. Histopathology 1994: 24: 405.
2. Ralfkiaer E, Saati TA, Bosq J et al. Immunohistochemical characterization of cutaneous lymphomas other than mycosis fungoides. J Clin Pathol 1986: 39: 353.
3. Wood GS, Burke JS, Horming S et al. The immunologic and clinicopathologic heterogeneticity of cutaneous lymphomas other than mycosis fungoides. Blood 1983: 62: 464.
4. Beljaards RC, Meijer CJLM, Scheffer E et al. Prognostic significance of CD30 (ki-1/Ber-H2) expression in primary cutaneous large cell lymphomas of T-cell origin. A clinicopathologic and immunohistochemical study in 20 patients. Am J Pathol 1989: 135: 1169.
5. Willemze R, Beljaards RC. Spectrum of primary cutaneous CD30 (ki-1)-positive lymphoproliferative disorders. J Am Acad Dermatol 1993: 28: 973.
6. Chooback L, Felix CA, Salhany KE et al. Overexpression of P53 protein in cutaneous T-cell lymphoma (CTCL): relationship to large cell transformation and disease progression J Invest Dermatol 1995: 104: 674
7. Lo Coco F, Gaidano G, Louie DC et al. P53 mutations are associated with histologic transformation of follicular lymphoma. Blood 1993: 82: 2289.
8. Pezzella F. The bcl2 protein and its gene in hematological and epithetical tumors. In: Polli EE, ed. Molecular basis of human disease. Amsterdam: Excerpta Medica, 1993: 241.
9. Lauritzen AF, Vejlsgaard GL, Hon-Jensen K, Ralfkiaer E. P53 protein expression in cutaneous T-cell lymphoma. Br J Dermatol 1995: 133: 32.
10. Hollestein M, Sidransky D, Vogelstein B, Harris CC. P53 mutations in human cancer. Science 1991: 253: 49.
11. Levine AJ, Momand J, Finlay CA. The p53 tumor suppressor gene. Nature 1991: 351: 453.
12. Piris MA, Pezzella F, Martinez-Montero JC et al. P53 and bcl2 expression in high-grade B-cell lymphomas; correlation with survival time. Br J Cancer 1994: 69: 337.
13. Hermine O, Haioun C, Lepage E et al. Prognostic significance of bcl2 protein expression in aggressive non-Hodgkin's lymphoma. Blood 1996: 87: 265.1
14. Pezzella F, Tse AGD, Cordell JL. Expression of the bcl2 oncogene protein is not specific for the 14;18 chromosomal translocation. Am J Pathol 1990: 137: 225.
15. Rose DSC, Maddox PH, Brown DC. Which proliferation markers for routine immunohistology? A comparison of five antibodies. J Clin Pathol 1994: 47: 1010.
16. Holden JA, Perkins SL, Snow GW, Kjeldsberg CR. Immunohistochemical staining for DNA topoisomerase II in non-Hodgkin's lymphomas. Am J Clin Pathol 1995: 104: 34.
17. Kanavaros P, Ioannidou D, Tzardi M et al. Mycosis fungoides: Expression of C-myc P62, P53, bcl2 and PCNA proteins and absence of association with Epstein-Barr virus. Path Res Pract 1994: 190: 767.
18. McGregor JM, Dublin EA, Levison DA et al. P53 immunoreactivity is uncommon in primary cutaneous lymphoma. Br J Dermatol 1995: 132: 353.
19. Beylot Barry M, Vergier B, De Mascarel et al. P53 oncoprotein expression in cutaneous lymphoproliferations. Arch Dermatol 1995: 131: 1019.
20. Van Haselen CW, Toonstra J, Van der Putte SCJ, Van Vloten WA. Diminished apoptosis of tumor cells in large cell cutaneous T-cell lymphomas. Consequences for cell biological behaviour and therapy resistance. In: Pieters P, Kaspers GJL, Veerman AJP, eds. Drug resistance in leukaemia and lymphoma. Singapore: Harwood Academic Publishers, 1996: 129.
21. Cesarman E, Inghirami G, Chadburn A, Knowles DM. High levels of p53 protein expression do not correlate with mutations in anaplastic large cell lymphoma. Am J Pathol 1993: 143: 845.
22. Neri A, Fracchiolla NS, Roscetti E et al. Molecular analysis of cutaneous B- and T-cell lymphomas. Blood 1995: 86: 3161.
23. Szekely L, Selivanova G, Magnusson KP et al. EBNA-5, an Epstein-Barr virus-encoded nuclear antigen, binds to the retinoblastoma and p53 proteins. Proc Natl Acad Sci USA 1993: 90: 5455.
24. Momand J, Zambetti GP, Olson DC et al. The mdm-2 oncogone product forms a complex with the p53 protein and inhibits p53 mediated transactivation. Cell 1992: 69: 1237.
25. Lopa TEG. Infrequent association of Epstein Barr virus with CD30 positive anaplastic large cell lymphoma. Am J Surg Pathol 1995: 19: 42.
26. Kaudewitz P, Szeimies RM. Proliferation activity in skin lesions of mycosis fungoides: prognostic and pathophysiologic implications. In: Lambert WC, Gianotti B, van Vloten WA, eds. Basic mechanisms of physiologic and aberrant lymphoproliferation in the skin. New York: Plenum Press, 1994: 317.
27. Orchard GE, Whittaker S, Trotter M and Smith NP. Lymphomatoid papulosis: an immunohistochemical analysis of CD30 positive atypical cells. Br J Dermatol 1995: 45(suppl): 56.
28. Korkolopoulou P, Oates J, Kittas C, Crocker J. P53, c-myc p62 and proliferating cell nuclear antigen (PCNA) expression in non-Hodgkin's lymphomas. J Clin Pathol 1994: 47: 9.